Literature DB >> 27579809

Risk Differences Between Prediabetes And Diabetes According To Breast Cancer Molecular Subtypes.

A Crispo1, L S A Augustin1,2, M Grimaldi1, F Nocerino1, A Giudice1, E Cavalcanti3, M Di Bonito3, G Botti3, M De Laurentiis4, M Rinaldo4, E Esposito4,5, G Riccardi5, A Amore6, M Libra7, G Ciliberto8, D J A Jenkins2, M Montella1.   

Abstract

Hyperglycemia and hyperinsulinemia may play a role in breast carcinogenesis and prediabetes and diabetes have been associated with increased breast cancer (BC) risk. However, whether BC molecular subtypes may modify these associations is less clear. We therefore investigated these associations in all cases and by BC molecular subtypes among women living in Southern Italy. Cases were 557 patients with non-metastatic incident BC and controls were 592 outpatients enrolled during the same period as cases and in the same hospital for skin-related non-malignant conditions. Adjusted multivariate logistic regression models were built to assess the risks of developing BC in the presence of prediabetes or diabetes. The analyses were repeated by strata of BC molecular subtypes: Luminal A, Luminal B, HER2+, and Triple Negative (TN). Prediabetes and diabetes were significantly associated with higher BC incidence after controlling for known risk factors (OR = 1.94, 95% CI 1.32-2.87 and OR = 2.46, 95% CI 1.38-4.37, respectively). Similar results were seen in Luminal A and B while in the TN subtype only prediabetes was associated with BC (OR = 2.43, 95% CI 1.11-5.32). Among HER2+ patients, only diabetes was significantly associated with BC risk (OR = 3.04, 95% CI 1.24-7.47). Furthermore, when postmenopausal HER2+ was split into hormone receptor positive versus negative, the association with diabetes remained significant only in the former (OR = 5.13, 95% CI 1.53-17.22). These results suggest that prediabetes and diabetes are strongly associated with BC incidence and that these metabolic conditions may be more relevant in the presence of breast cancer molecular subtypes with positive hormone receptors. J. Cell. Physiol. 232: 1144-1150, 2017.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2016        PMID: 27579809     DOI: 10.1002/jcp.25579

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  4 in total

1.  Relationship between Diabetes and Diabetes Medications and Risk of Different Molecular Subtypes of Breast Cancer.

Authors:  Hongjie Chen; Linda S Cook; Mei-Tzu C Tang; Deirdre A Hill; Charles L Wiggins; Christopher I Li
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-08-08       Impact factor: 4.254

2.  A prospective study of type 2 diabetes, metformin use, and risk of breast cancer.

Authors:  Y-M M Park; D B Bookwalter; K M O'Brien; C L Jackson; C R Weinberg; D P Sandler
Journal:  Ann Oncol       Date:  2021-01-29       Impact factor: 32.976

3.  Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients.

Authors:  Gerardo Botti; Francesca Collina; Giosuè Scognamiglio; Federica Rao; Valentina Peluso; Rossella De Cecio; Michela Piezzo; Gabriella Landi; Michelino De Laurentiis; Monica Cantile; Maurizio Di Bonito
Journal:  Int J Mol Sci       Date:  2017-02-21       Impact factor: 5.923

4.  Investigating a multigene prognostic assay based on significant pathways for Luminal A breast cancer through gene expression profile analysis.

Authors:  Haiyan Gao; Mei Yang; Xiaolan Zhang
Journal:  Oncol Lett       Date:  2018-02-02       Impact factor: 2.967

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.